Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led the ...

Under the terms of the J&J deal, Isomorphic will be responsible for in silico predictions and design, while the US group will ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

Isomorphic Labs was spun out of Google DeepMind, after the tech giant achieved one of the biggest biological breakthroughs in the last 50 years. Demis Hassabis is at the helm of both Isomorphic and ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital as a backer. By Michael J. de la Merced Reporting from London Over the ...

Silicon Valley and Wall Street are pouring billions into AI drug discovery in a high-stakes bet to “solve” disease.

Isomorphic Labs, which uses artificial intelligence for ‍drug discovery, expects to have its first clinical trials by the end of ‌2026, founder and ‌CEO Demis Hassabis said on Tuesday. The comments, ...